College of Pharmacy, The University of Findlay, Findlay, OH, USA.
Expert Rev Cardiovasc Ther. 2022 Jul;20(7):529-541. doi: 10.1080/14779072.2022.2098118. Epub 2022 Jul 8.
Heart failure is one of the cardiovascular diseases that impacts the geriatric population. As new clinical trials investigating heart failure are conducted, groundbreaking information is assessable to further evolve the treatment. To correctly improve the quality of life of elderly patients, it is critical to evaluate the safety and efficacy of new and improved therapy regimens.
In reviewal of the 2021 and 2022 updated guidelines, the safety and efficacy of the newly indicated medications will be addressed. The new indications cover sacubitril/valsartan and two SGLT2 inhibitors: dapagliflozin and empagliflozin. An introduction to the medications discussed covers the pharmacology before addressing the efficacy and safety considerations in the elderly population. Furthermore, prime drug-drug interactions associated with the two classes of medications will be considered as well as providing possible solutions to further create the safest drug therapy for geriatric patients with common comorbidities.
The two classes of medications, the ARNI and SGLT2 inhibitors, are well-tolerated amongst the elderly population. With the release of new guidelines, the updated medications will provide safer and better therapy in this disease state for geriatrics. One major limitation includes the high cost of these brand-named medications.
心力衰竭是影响老年人群体的心血管疾病之一。随着新的心力衰竭临床试验的开展，可评估开创性信息以进一步改进治疗方法。为了正确提高老年患者的生活质量，评估新的和改进的治疗方案的安全性和疗效至关重要。
在回顾 2021 年和 2022 年更新的指南时，将讨论新指定药物的安全性和疗效。新的适应证涵盖沙库巴曲缬沙坦和两种 SGLT2 抑制剂：达格列净和恩格列净。在讨论这些药物之前，先介绍药物的药理学，然后讨论在老年人群中评估疗效和安全性的注意事项。此外，还将考虑与这两类药物相关的主要药物相互作用，并提供可能的解决方案，以进一步为患有常见合并症的老年患者制定最安全的药物治疗方案。
这两类药物，即 ARNI 和 SGLT2 抑制剂，在老年人群中耐受性良好。随着新指南的发布，更新的药物将为老年患者的这种疾病状态提供更安全、更有效的治疗。一个主要的局限性是这些品牌药物的高成本。
